X-Vis 1500 Injection contains Cefuroxime 1500 mg, a second-generation cephalosporin antibiotic with a broad spectrum of activity against both Gram-positive and Gram-negative bacteria. It is indicated for the treatment of various bacterial infections including respiratory tract infections, urinary tract infections, skin and soft tissue infections, bone and joint infections, and septicemia caused by susceptible organisms. Cefuroxime exerts its bactericidal effect by inhibiting bacterial cell wall synthesis, leading to cell lysis and death. X-Vis 1500 Injection is administered via intramuscular or intravenous routes, ensuring rapid systemic distribution and effective plasma concentrations. The dosage and duration of therapy should be tailored according to the severity of the infection, patient age, renal function, and clinical response. It is contraindicated in patients with known hypersensitivity to cephalosporins or penicillins due to potential cross-reactivity. Common adverse effects may include gastrointestinal disturbances, injection site reactions, and hypersensitivity reactions. Caution is advised in patients with renal impairment, and dosage adjustments may be necessary. X-Vis 1500 Injection should be used under strict medical supervision, with appropriate microbiological testing to confirm susceptibility and monitor therapeutic outcomes, thereby minimizing the risk of resistance development.